Objective-Lipid-laden macrophages or foam cells are characterized by massive cytosolic lipid droplet (LD) deposition containing mostly cholesterol ester (CE) derived from the lipoproteins cleared from the arterial wall. Cholesterol efflux from foam cells is considered to be atheroprotective. Because cholesterol is effluxed as free cholesterol, CE accumulation in LDs may limit free cholesterol efflux. Our objective was to identify proteins that regulate cholesterol trafficking through LDs. Approach and Results-In a proteomic analysis of the LD fraction of RAW 264.7 macrophages, we identified an evolutionarily conserved protein with a canonical GXSXG lipase catalytic motif and a predicted α/β-hydrolase fold, the RIKEN cDNA 1110057K04 gene, which we named LD-associated hydrolase (LDAH). LDAH association with LDs was confirmed by immunoblotting and immunocytochemistry. LDAH was labeled with a probe specific for active serine hydrolases. LDAH showed relatively weak in vitro CE hydrolase activity. However, cholesterol measurements in intact cells supported a significant role of LDAH in CE homeostasis because LDAH upregulation and downregulation decreased and increased, respectively, intracellular cholesterol and CE in human embryonic kidney-293 cells and RAW 264.7 macrophages. Mutation of the putative nucleophilic serine impaired active hydrolase probe binding, in vitro CE hydrolase activity, and cholesterol-lowering effect in cells, whereas this mutant still localized to the LD. LDAH upregulation increased CE hydrolysis and cholesterol efflux from macrophages, and, interestingly, LDAH is highly expressed in macrophage-rich areas within mouse and human atherosclerotic lesions.
T he lipid-laden macrophage or foam cell is central to the initiation and progression of atherosclerosis. 1 Foam cells are derived from circulating monocytes that migrate to the subendothelium and differentiate into macrophages in response to inflammatory stimuli triggered by, among other factors, the deposition of various forms of modified low-density lipoprotein (LDL). Macrophages take up the modified LDL by scavenger receptor-mediated endocytosis in an unfettered way and consequently need to manage a large influx of cholesterol. After internalization, the modified LDL-derived cholesterol ester (CE) is hydrolyzed in the lysosomes by the acid lipase, and free cholesterol (FC) is exported to the cytoplasm. Surplus cytoplasmic FC is re-esterified in the endoplasmic reticulum (ER) by acetyl-coenzyme A acetyltransferase 1 (ACAT1) and stored as CE in cytoplasmic lipid droplets (LDs). 2, 3 The LD CE undergoes a continuous cycle of hydrolysis and re-esterification, and the FC generated by the hydrolytic arm of the cycle is known to constitute a suitable substrate for efflux. 4 It is, therefore, conceivable that a low rate of CE hydrolysis may limit the amount of FC available for efflux and that, conversely, FC supply to efflux pathways could be increased by increasing the rate of CE hydrolysis, which in turn would promote reverse cholesterol transport from atherosclerotic lesions. Consequently, considerable efforts have been made to elucidate the identity of the enzymes that hydrolyze the CE stored in LDs of foam cells, generically known as neutral cholesterol ester hydrolases (NCEH) because they function at the cytoplasmic neutral pH.
The most obvious candidate NCEH was hormone-sensitive lipase (HSL), a robust esterase/lipase expressed mainly in adipose and steroidogenic tissues, where it associates with LDs and catalyzes the hydrolysis of triacylglycerol (TAG) and CE, respectively. 5 However, lysates of HSL-knockout mouse peritoneal macrophages displayed significantly reduced but not fully abolished CE hydrolase activity, 6, 7 and the mobilization of CE stores was similar in wild-type and HSL-knockout mouse peritoneal macrophages, indicating that other enzymes are able to catalyze CE hydrolysis in macrophages. 7, 8 Furthermore, although HSL is expressed in murine macrophages, studies in human monocytes, macrophages, and human atherosclerotic lesions have reported extremely low or even undetectable levels of HSL expression. 9 Two additional candidate NCEHs, that were named CEH and NCEH1, were identified in reverse transcription-polymerase chain reaction screenings and in silico searches, respectively, that were aiming to uncover proteins with lipase-compatible sequences. 10, 11 CEH is identical to human hepatic carboxylesterase 1, also known as triglyceride hydrolase. 12 Carboxylesterases are primarily ER-associated proteins, with their catalytic domains facing the ER lumen, 12 although, interestingly, CEH was shown to remain in the cytosol and to associate with LDs in lipid-laden THP-1 macrophages, an obligatory step for the subsequent hydrolysis of CE present in the LDs. 13 Although CEH/carboxylesterase 1/triglyceride hydrolase is expressed in human macrophages, its mouse ortholog, carboxylesterase 3/triglyceride hydrolase, is not expressed in macrophages, suggesting that other enzymes are involved in CE hydrolysis in HSL-knockout murine macrophages. 12 The third candidate, NCEH1, also named KIAA1363 or arylacetamide deacetylase-like 1, is also an ER-associated protein with its active site situated in the ER lumen. 12, 14 Consistent with its intracellular localization, it was reported that CE hydrolysis was reduced in microsomes but not in soluble cytosolic fractions of NCEH1/KIAA1363/arylacetamide deacetylase-like 1-deficient macrophages, 6 and the hydrolysis of preformed CE stores was similar in mouse peritoneal macrophages isolated from wild-type and NCEH1/KIAA1363/arylacetamide deacetylase-like 1-deficient mice. 7 It is noteworthy that in foam cells the hydrolysis of the LD CE is not exclusively dependent on NCEHs because it was reported that LDs could be delivered to lysosomes via autophagy, where the acid lipase hydrolyzes CE to generate FC for efflux. 15 Interestingly, inhibition of the neutral and lysosomal pathways of LD-associated CE hydrolysis increased macrophage CE mass in a cumulative fashion, and although inhibition of each individual pathway decreased CE hydrolysis, only the inhibition of both pathways totally abolished CE hydrolysis, indicating that the 2 pathways cannot fully compensate each other. Thus, although multiple enzymes may be able to hydrolyze CE in foam cells at different points of the CE cycle, the current evidence suggests that there may be additional NCEHs acting on LDs that are yet to be identified. Here, we have performed a proteomic analysis of the LD fraction of RAW 264.7 macrophages in which we have identified a serine hydrolase we have named LD-associated hydrolase (LDAH). Results from biochemical cholesterol measurements and cholesterol trafficking experiments implicate a role of LDAH in CE turnover, and LDAH expression is enriched in macrophage-rich areas within mouse and human atherosclerotic lesions.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Identification of a Novel LD-Associated Serine Hydrolase in Macrophages
Purified LD-associated proteins isolated from lipid-laden RAW 264.7 macrophages were identified by nano liquid chromatography-tandem mass spectrometry. The LD protein band pattern ( Figure 1A ) was consistent in various LD isolations. Forty proteins were identified based on ≥3 matching peptides, of which 11 (≈28%) had not previously been found to be associated with LDs of mammalian cells (Table 1) . Among them, we identified a protein with an annotated esterase/lipase domain, the RIKEN cDNA 1110057K04 gene (GI: 55777092), the human homolog of which, named UPF0554 protein C2orf43 (GI: 11345458), had been classified as a member of the metabolic serine hydrolase family of proteins, which includes most known mammalian esterases and lipases. 16 To simplify, we named this protein LDAH, and we will refer to the mouse homolog as mLDAH and to the human homolog as hLDAH. Although to our knowledge endogenous LDAH had not been identified in previous LD proteomics in mammalian cells, the LDAH Drosophila melanogaster homolog, named CG9186, had previously been identified in 2 proteomic analyses of LDs isolated from Drosophila embryos and late third instar larval fat bodies, 17, 18 and while this manuscript was in preparation, Thiel et al 19 showed LD localization of both the fly and mouse overexpressed proteins.
Eleven mLDAH matching peptides were identified in the liquid chromatography-tandem mass spectrometry analysis, the highest number in fragment 5 ( Table II in the online-only  Data Supplement) , and these peptides aligned with 6 different fragments within the protein sequence ( Figure IA and IB in the online-only Data Supplement). To confirm that endogenous LDAH localizes to the LD, we generated an anti-mLDAH antibody that showed specificity in cell lysates with mLDAH overexpression and downregulation ( Figure  1B ). Immunoblots performed on the same LD and cytoplasmic protein fractions used for the proteomic analysis detected enriched mLDAH in the LD fraction ( Figure 1C ). The purity of this LD fraction was verified by immunoblotting against cytoplasmic (GAPDH), ER (calnexin), Golgi (GM130), and LD (perilipin 2 and adipose triglyceride lipase) markers ( Figure 1C ). Furthermore, after subfractionation of cytoplasms at 100 000g, mLDAH was detected predominantly in the 100 000g supernatants, which is consistent with the fact that its sequence does not contain a signal peptide ( Figure  1D ). LD association of LDAH was also confirmed by immunofluorescence in RAW 264.7 macrophages transfected with flag-mLDAH, which showed protein enrichment at the LD perimeter ( Figure 1E ). Interestingly, although Thiel et al 19 reported that LDAH induced LD clustering and in some cases fusion in nonmonocytic cell lines that were treated with oleic acid, we did not observe changes in LD phenotype in cholesterol-laden macrophages with flag-mLDAH overexpression. LDAH was also found, by immunoblotting, in LD fractions isolated from flag-mLDAH-transfected HeLa cells, and microscopy analysis of lipid-laden HeLa cells showed mLDAH colocalization with perilipin 2 at the LD perimeter ( Figure 1F ; Figure II in the online-only Data Supplement). Furthermore, transfection with hLDAH-green fluorescent protein also showed localization of the human homolog at the LD perimeter ( Figure 1G ). Collectively, these data support that LDAH is a genuine LD-associated protein.
LDAH Has Esterase/Lipase Features and Plays a Role in Cholesterol Homeostasis
mLDAH is a 326-aa protein with a calculated molecular mass of ≈36 kD that is highly conserved through evolution (see examples in Figure 2 ). Esterases/lipases are typically built in an α/β-hydrolase fold structure, and in most cases, their catalytic apparatus involves 3 residues that are responsible for the nucleophilic attack on the carbonyl carbon atom of the ester bond: a nucleophilic serine, an acid residue (glutamate or aspartate), and a histidine. Patatin domain-containing lipases such as adipose triglyceride lipase are an exception because they use serine-aspartate dyads for catalysis instead of catalytic triads. 20 A highly conserved feature is that the nucleophilic serine is in a consensus GXSXG sequence, which is usually positioned in-between a β-strand and an α-helix, where the protein folds forming a sharp turn. mLDAH sequence analysis with the PSIPRED software 21 predicted a secondary structure that was compatible with that expected from a protein containing an α/β-hydrolase fold ( Figure 2 ). Furthermore, mLDAH Figure 1 . Identification of a novel candidate lipid droplet (LD)-associated cholesterol ester (CE) hydrolase. A, LD proteins isolated from RAW 264.7 macrophages were resolved by SDS-PAGE and stained with Coomassie Blue. Six gel fragments containing most protein bands were analyzed by nano liquid chromatography-tandem mass spectrometry. B, A custom anti-mouse LD-associated hydrolase (mLDAH) antibody was generated, and its specificity was confirmed in HeLa cells transfected with mouse and human LDAH-green fluorescent protein (GFP) and flag-LDAH and in RAW 264.7 macrophages with short hairpin RNA (shRNA)-mediated mLDAH downregulation. C, Immunoblot with anti-mLDAH on the cytosolic and LD fractions that were used for the proteomic analysis. Immunoblots with antibodies against GAPDH (cytoplasmic protein), calnexin (endoplasmic reticulum protein), GM130 (Golgi protein), and perilipin 2 (PLIN2) and adipose triglyceride lipase (ATGL; LD proteins) verified the purity of the LD fraction. D, Immunoblot with anti-mLDAH performed on total cytosol (TC), soluble 100 000g fractions (S100), and 100 000g membrane pellets (M) of RAW 264.7 macrophages. E, Immunostaining with anti-flag (green) on acetylated low-density lipoprotein-treated (50 µg/mL, 18 hours) RAW 264.7 macrophages transfected with flag-mLDAH. LipidTox (red) was used to stain LDs. F, Immunoblot with anti-flag on total lysate and LD fractions of flag-mLDAH-transfected HeLa cells treated with oleic acid (360 µmol/L; 18 hours). G, Fluorescence microscopy on HeLa cells transfected with hLDAH-GFP (green) and treated with oleic acid (360 µmol/L, 18 hours). LipidTOX was used to label LDs (Red). Cyto indicates cytoplasmic fraction; and MW, molecular weight marker.
LD MW Cyto
contains a central GXSXG motif harboring a putative nucleophilic serine (S140), and a conserved aspartate (D272) and a conserved histidine (H291) could complete the catalytic triad. These 3 candidate catalytic amino acids are predicted to be positioned between strands and helixes ( Figure 2 ).
To test whether LDAH is an active serine hydrolase, we used a metabolic probe, desthiobiotin-fluorophosphonate (DTB-FP) that specifically and covalently binds to functionally active serine hydrolases and inhibits their activity. 16 As seen in Figure 3A , wild-type mLDAH was labeled with DTB-FP, whereas a S140->C mutant, in which the predicted active-site serine was replaced by a cysteine, was not labeled. To test whether LDAH can hydrolyze CE, we performed cholesterol esterase activity assays in which HeLa cell lysates were assayed against 14 C-labeled CE emulsified with phospholipids. 22 Data from these experiments showed increased CE hydrolysis in lysates from cells with mLDAH overexpression, which was inhibited by S140->C mutation or by preincubation with DTB-FP, although the activity was much weaker than that seen in extracts of cells transfected with HSL ( Figure 3B ; Figure IIIA in the online-only Data Supplement). Conversely, no activity against TAG was detected ( Figure IIIB in the online-only Data Supplement). The results of experiments using cell-free extracts do not necessarily represent the protein's role in intact cells. Because gene expression manipulations in macrophages are challenging, to test whether LDAH plays a role in cholesterol homeostasis in intact cells, first we performed LDAH gain-and loss-of-function experiments in human embryonic kidney-293 cells that remained untreated or were treated with cholesterol-methyl-β-cyclodextrin, a system that allows cholesterol loading in a scavenger receptor-independent fashion. 23 CE was readily detectable in cholesterol-methyl-β-cyclodextrin-treated cells, and as expected, CE accumulation was paralleled by the inclusion of abundant cytoplasmic LDs ( Figure 3C ; Figure IV in the online-only Data Supplement). Interestingly, CE and total cholesterol levels were ≈50% and ≈25% lower, respectively, in cells transfected with mLDAH, whereas transfection with an S140->C mutant did not affect total cholesterol or CE levels ( Figure 3C ). Furthermore, knocking down endogenous hLDAH by ≈75% resulted in ≈2-fold increase in intracellular CE and ≈25% increase in total cholesterol ( Figure 3D ). Of note, the S140->C mutation did not affect LDAH localization to the LD ( Figure 3E ). Thus, DTB-FP labeling confirmed the prediction that LDAH is an active serine hydrolase, and although experiments using lysates of cells transfected with mLDAH showed relatively weak in vitro activity, gain-and loss-of-function experiments in intact cells indicated that LDAH plays a significant role in cholesterol homeostasis.
LDAH Upregulation Increases CE Turnover and Cholesterol Efflux in Macrophages
To test whether LDAH also plays role in CE accumulation in macrophages, we treated RAW 264.7 macrophages with acetylated LDL (acLDL), a form of modified LDL avidly internalized by macrophages. AcLDL loading increased CE content by ≈10-fold and total cholesterol mass by ≈2to 3-fold. However, similar to the observations in human embryonic kidney-293 cells, these parameters were markedly affected by LDAH gainand loss-of-function, which decreased and increased, respectively, intracellular total cholesterol and CE levels ( Figure 4A and 4B). These data were consistent in several independent experiments. In addition, lentiviral vectors encoding 3 different short hairpin RNAs were tested for LDAH downregulation. Two of them reduced LDAH protein level by ≈50%, which was associated with increased CE, whereas one of them did not affect either LDAH or CE levels ( Figure V Based on its localization to the LD surface and on its effects on CE levels, we hypothesized that LDAH promotes the turnover of the CE stored in LDs. After internalization by macrophages, the CE carried by the lipoproteins is hydrolyzed to FC in the lysosomes, and excess cytoplasmic FC is re-esterified in the ER and stored as CE in LDs. To specifically assess the turnover of the LD CE depots, RAW 264.7 macrophages were incubated with cold acLDL and pulsed with 3 H-labeled oleic acid to label the newly synthesized CE as 3 H-oleic-cholesterol. This was followed by a chase period in which cholesterol turnover was promoted by adding the cholesterol acceptor apolipoprotein A1 to the culture media, and re-esterification was blocked with an ACAT1 inhibitor. As seen in Figure 4C , cells transfected with flag-mLDAH displayed a higher rate of 3 H-oleic-cholesterol hydrolysis than flag-transfected control cells. Next, we asked whether LDAH upregulation also results in increased cholesterol efflux. The 2 main transporters involved in cholesterol efflux are ATP-binding cassette A1 and G1 (ABCA1 and ABCG1), which promote efflux to lipid-poor apolipoprotein A1 and high-density lipoprotein particles, respectively. ABCA1 and ABCG1 can act sequentially with ABCA1 initiating the formation of nascent high-density lipoprotein particles, which then acquire additional lipids via ABCG1. 24 Therefore, to take into consideration both the ABCA1-and ABCG1-mediated efflux, RAW 264.7 macrophages were cholesterol loaded with 3 H-cholesterol-labeled acLDL, and after washing and equilibration, apolipoprotein A1 was added to the culture media to induce efflux. As seen in Figure 4D , although early efflux was similar in macrophages with and without LDAH overexpression, the amount of cholesterol effluxed increased over time at a higher rate in cells transfected with flag-mLDAH than in flag-transfected controls. Interestingly, these results are consistent with those of other interventions at the LD level, which also showed a significant response on later rather than earlier efflux. 3, 15, 25 The changes in efflux seen in cells with mLDAH overexpression were not because of increased expression of ABCA1 or ABCG1 ( Figure VII in the online-only Data Supplement).
To rule out the possibility that the differences seen in the previous experiments were because of changes in cholesterol uptake, RAW 264.7 macrophages were loaded with 3 H-cholesterol-labeled acLDL in the absence of serum for 4 and 24 hours, and the 3 H-cholesterol in the FC and CE fractions was quantified. As seen in Figure 4E , the total amount of cholesterol (free+esterified) was similar between flag-mLDAH-and flag-transfected macrophages, indicating that LDAH upregulation did not affect cholesterol uptake. At the earlier time point most cholesterol (≈80%) still remained as FC, whereas at the 24-hour time point ≈40% to 50% of the cholesterol was incorporated into the CE pool. However, at both time points, the percentage of acLDL-derived cholesterol in the form of FC and CE was higher and lower, respectively, in macrophages with LDAH overexpression ( Figure 4F ). Thus, LDAH upregulation did not affect the rate of cholesterol uptake by macrophages, but it increased the hydrolysis of re-esterified CE, and this was associated with increased cholesterol efflux.
LDAH Is Expressed in Mouse and Human Atherosclerotic Lesions
LDAH expression was not restricted to the RAW 264.7 cell line, but it was also expressed in primary mouse peritoneal macrophages and bone marrow-derived macrophages. (Figure 5A ). Regarding atherosclerotic lesions, quantitative real-time polymerase chain reaction analysis detected ≈2.5-fold higher mLDAH mRNA in RNA isolated by laser capture microdissection from lesional macrophages/foam cells than in RNA isolated from apolipoprotein E-deficient mice whole aortas ( Figure 5B) . At the protein level, immunohistological analyses readily detected immunoreactive LDAH predominantly in macrophage-rich areas within the lesions ( Figure  5C ). With respect to other tissues, LDAH mRNA was ubiquitously detected, with higher levels found in white adipose tissue, liver, heart, and brown adipose tissue ( Figure 5D ). Protein levels were high in liver and white and brown adipose tissues, but lower levels were also observed in testis, stomach, brain, kidney, and pancreas. Although LDAH mRNA levels were detected in heart and muscle, no protein band of the expected size was observed in these tissues ( Figure 5E ). Interestingly, LDAH levels in mouse macrophages were relatively high, comparable with the levels seen in the tissues with higher LDAH expression such as white adipose tissue and brown adipose tissue ( Figure 5F ). Given its role in cholesterol metabolism and the fact that LDAH is expressed by foam cells, we speculated that LDAH expression could be regulated by cholesterol loading. However, as seen in Figure 5G , LDAH expression was not affected by treatment with acLDL, whereas the expression of the LD-associated protein perilipin 2 was highly induced.
To test whether LDAH is also expressed in human atherosclerotic lesions, we generated anti-hLDAH antibody that specifically recognized hLDAH ( Figure 6A ). By immunoblotting, hLDAH was detected in THP-1 macrophages, a human monocytic cell line, and, more importantly, in human carotid endarterectomy specimens ( Figure 6B ). On the contrary, in agreement with previous reports, 8, 26 HSL levels were sensibly lower in THP-1 macrophages than in RAW 264.7 macrophages, and HSL was undetectable in endarterectomy specimens ( Figure 6C ). In addition, in line with the mouse data, immunohistological analyses of endarterectomy specimens detected hLDAH predominantly in macrophage-rich areas within the human lesions ( Figure 6D ). Furthermore, LDAH was also detected in lysates of human monocytes and monocyte-derived macrophages ( Figure 6E ). Thus, LDAH is highly expressed in mouse and human macrophages of different sources, and the protein is expressed in mouse and human atheroma, predominantly in foam cell-rich areas within the lesions.
Discussion
The lipid-laden macrophage or foam cell is a hallmark of atherosclerotic lesions, and there is compelling evidence that enhancing reverse cholesterol transport from foam cells is an effective antiatherogenic strategy. 27 In macrophages, cholesterol is stored as CE but effluxed as FC. 2 Thus, theoretically the hydrolysis of the CE accrued within LDs could be considered as a preliminary and perhaps limiting step for cholesterol efflux and reverse cholesterol transport from atherosclerotic lesions, and proteins controlling the process could become pharmacological targets to ameliorate atherogenesis. Unfortunately, the identity of the proteins that regulate the hydrolysis of the CE stored in LDs of foam cells is still far from clear. Most known lipases and esterases belong to the subfamily of metabolic serine hydrolases, and, therefore, it is likely that the enzymes involved in CE hydrolysis in macrophages are among the ≈115 members of this family and probably among the ≈50% family members with unknown function. 16 Interestingly, our macrophage LD proteomics led to the identification of LDAH, an evolutionarily conserved protein that had been classified as a metabolic serine hydrolase. 16 To our knowledge, the only functional characterization of any of the LDAH homologs was recently reported by Thiel et al, 19 who found that overexpression of CG9186 or mLDAH fused to green fluorescent protein caused LD clustering in cells cultured with oleic acid, which was abrogated by deleting the 106 C-terminal amino acids but not by mutating the putative nucleophilic serine, suggesting that this phenotype is not related to the protein's hydrolytic activity. In addition, neither the Drosophila or mouse homologs displayed activity toward TAG, diacylglycerol, or monoacylglycerol nor did CG9186 overexpression change TAG content in Drosophila Kc167 cells, whereas CG9186 knockdown actually decreased TAG in flies, facts that are at odds with the protein playing a role in TAG hydrolysis. Thus, to date no enzymatic activity for this protein had been demonstrated, and a possibility to take into consideration was that LDAH is not an active hydrolase. For example, comparative gene identification-58 is an α/β-hydrolase fold protein that associates with LDs and is considered to be an activator of adipose triglyceride lipase, a rate-limiting enzyme in TAG hydrolysis. However, comparative gene identification-58 contains a pseudocatalytic triad in which the nucleophilic serine in the GXSXG motif is replaced by an asparagine and, therefore, is unlikely that it exhibits hydrolase activity. 28 Although LDAH contains the actual GXSXG motif, it was important to demonstrate that the protein is an active hydrolase. This was shown by labeling experiments with DTB-FP, a probe that when hydrolyzed by serine hydrolases remains covalently bound to the nucleophilic serine. With respect to the LDAH substrates, in agreement with the data by Thiel et al, 19 our results did not show increased TAG hydrolase activity in lysates of HeLa cells with LDAH overexpression. Interestingly, extracts of mLDAH-transfectd HeLa cells showed significantly increased CE hydrolase activity, although the in vitro activity was much weaker than that seen in lysates of HSL-overexpressing HeLa cells. In vitro conditions that work well for one enzyme may not work as well or even be detrimental to others. However, we assayed CE hydrolase activity in cell lysates under different conditions, including phosphatidylcholine/phosphatidylinositol micelles with or without taurocholate, PC alone, or PI of different sources, and the CE hydrolase activity in lysates of cells transfected with HSL was consistently higher than that of lysates of cells transfected with LDAH (data not shown). This is not surprising because HSL is a robust CE hydrolase that is highly expressed in tissues where adequate FC supply is critical for proper esteroidogenesis, whereas the high accumulation of CE seen in foam cells suggests that the CE may be hydrolyzed by enzymes with lower catalytic rates. 29, 30 However, the results of in vitro activity assays may not adequately reflect the protein's physiological relevance, for example, because of lack of other LD-associated proteins or cofactors that may modulate the protein's activity in vivo or because protein-protein interactions at the LD surface are disrupted on cell lysis. Experiments using intact cells provided stronger evidence that LDAH plays a role in cholesterol homeostasis because cellular CE content decreased when LDAH was overexpressed and increased when LDAH was downregulated, both in human embryonic kidney-293 and in RAW 264.7 cells. Interestingly, mutation of the nucleophilic serine impaired active hydrolase probe binding, in vitro lipase activity, and cholesterol-lowering effect in cells, whereas this mutant still localized to the LD. In addition, cholesterol trafficking experiments indicated that LDAH may be a promising candidate target for stimulating reverse cholesterol transport from foam cells because macrophages with LDAH overexpression showed increased CE turnover and efflux. Furthermore, LDAH's relatively high expression in macrophage-rich areas within atherosclerotic lesions also indicates that LDAH could be a suitable target to promote reverse cholesterol transport from the lesions. Although LD proteomic analyses may be technically challenging, they have the advantage over indirect screening methods that they allow circumventing ambiguity with the proteins' cellular localization. The intracellular localization of the proteins that regulate the CE cycle is not a trivial question. Part of the cycle takes place in the ER where FC is re-esterified by ACAT1, and, therefore, it could be argued that the ER could also be a potential site for therapeutic intervention. However, studies on ACAT1 inhibition have shown that raising FC levels inside the ER can give rise to adverse side effects. Compared with other cell membranes, the ER membrane is relatively poor in cholesterol, and it is well established that FC accumulation at the ER membrane, such as seen under ACAT1 inhibition, results in ER stress-mediated apoptosis, increased synthesis of inflammatory mediators, and, in vivo, in accelerated atherosclerosis with grossly necrotic lesions. 31, 32 However, FC accumulation in other cell compartments, such as the plasma membrane, is not as harmful to the macrophage, 33 and macrophages can tolerate perilipin 2 deficiency, which hampers their ability to accumulate cytoplasmic LDs, much better than ACAT1 inhibition. 34 Presumably, the ER FC levels would also increase if CE hydrolysis were to be mediated by ER lumen-resident enzymes. Thus, considering that the safety of a molecular intervention with potential therapeutic use may be as important as its efficiency, current evidence indicates that targeting proteins that mediate CE hydrolysis at the LD level is safer than targeting ER-resident proteins.
In conclusion, this study identifies a novel LD-associated serine hydrolase in macrophages and uncovers a role of the protein in cholesterol mobilization. Interestingly, in addition to foam cells, high LDAH levels are also seen in important metabolic tissues such as white adipose tissue, brown adipose tissue, and liver. Atherosclerosis development is closely related to several comorbidities, such as obesity, dyslipidemia, insulin resistance, and type 2 diabetes mellitus, which are also caused or aggravated by excessive lipid accumulation in tissues, and, accordingly, multiple lines of evidence have linked LD biology to their pathogenesis. 35 Thus, LDAH could be a significant player not only in atherogenesis but also in other lipid-related metabolic derangements.
The hydrolysis of the cholesterol ester (CE) accrued within lipid droplets (LDs) of foam cells is considered a limiting step for cholesterol efflux and reverse cholesterol transport from atherosclerotic lesions. Unfortunately, to date the identity of the enzymes responsible for CE hydrolysis at the LD level, generically known as neutral CE hydrolases, remains unclear. In a proteomic analysis of the LD fraction of RAW 264.7 macrophages, we have identified a novel serine hydrolase that we have named LD-associated hydrolase. Gain-and loss-of-function experiments in cell culture showed an inverse relationship between LD-associated hydrolase levels and intracellular cholesterol and CE levels, and LD-associated hydrolase upregulation promoted the hydrolysis of the CE stored in LDs, which was associated with increased cholesterol efflux. In vivo, LD-associated hydrolase is highly expressed in foam cell-rich areas within mouse and human atherosclerotic lesions. The data identify a potential new target to promote reverse cholesterol transport from atherosclerotic lesions.
Significance
